| Literature DB >> 33469746 |
Miriam Komaromy1,2, Miriam Harris3,4,5, Rob M Koenig6, Mary Tomanovich3, Glorimar Ruiz-Mercado3,7, Joshua A Barocas3,7.
Abstract
Entities:
Mesh:
Year: 2021 PMID: 33469746 PMCID: PMC7815181 DOI: 10.1007/s11606-020-06499-2
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 6.473
Staffing Model at COVID Recuperation Unit
| MD | 1.00 | 1.00 |
| Operation director | 1.00 | 1.00 |
| Discharge planner | 1.00 | n/a |
| Security staff | 4.00 | 4.00 |
| NP/PA | 1:88 | n/a |
| RN /LPN | 1:33 | 1:33 |
| Behavioral Health provider (counselor, social worker) | 1:88 | n/a |
| Harm reductionist | 1:88 | n/a |
| Nurse Tech/Medical Assistant | 1:22 | 1:22 |
| Operation staff | 1:22 | 1:22 |
Patient Characteristics During Treatment at COVID Recuperation Unit, Massachusetts 2020 (n = 226)
| Baseline characteristics | Full cohort, |
|---|---|
| Race/ethnicity | |
| Black, non-Hispanic | 88 (38.9%) |
| White, non-Hispanic | 71 (31.4%) |
| Hispanic or Latinx | 24 (10.6%) |
| Other | 3 (1.4%) |
| Unknown | 40 (17.7%) |
| Psychiatric comorbidities* + | |
| Depression | 86 (38.1%) |
| Anxiety | 78 (34.5%) |
| Post Traumatic Stress Disorder | 42 (18.6%) |
| Bipolar disorder | 37 (16.4%) |
| Schizophrenia/schizoaffective disorder | 26 (11.5%) |
| Brain injury | 13 (5.8%) |
| Active substance use at time of admission* + | |
| Alcohol | 64 (28.3%) |
| Opioids | 43 (19.0%) |
| Cocaine/crack | 43 (19.0%) |
| Methamphetamines | 4 (1.8%) |
| Benzodiazepines (not prescribed) | 3 (1.3%) |
*Not mutually exclusive
+Reported in electronic health record or medical provider’s assessment
Baseline Psychiatric Diagnoses and Active Substance Use Status in COVID Recuperation Unit, Massachusetts 2020 (n = 226)
| Baseline diagnoses | Full cohort, |
|---|---|
| Patients with psychiatric diagnoses | 179 (79.2%) |
| Patients with two or more psychiatric diagnoses | 86 (38.0%) |
| Patients with active drug use* | 94 (41.6%) |
| Patients who actively use more than one drug | 40 (17.7%) |
| Patients who have at least one psychiatric diagnosis and actively use at least one substance* | 68 (30.1%) |
*Excludes tobacco and marijuana use
Discharge/Transfer Events to Boston Medical Center for Medical/Psychiatric Complications from COVID Recuperation Unit, Massachusetts 2020 (n = 226)
| Rationale for evaluation | Full cohort, |
|---|---|
| Medical evaluation—apparent exacerbation of COVID-19 symptoms | 11 (4.9%) |
| Acute respiratory failure and/or low oxygen saturation | 5 (2.2%) |
| Acute cardiac issues | 4 (1.8%) |
| Coagulation issues | 1 (0.4%) |
| Renal issues | 1 (0.4%) |
| Medical evaluation—apparently unrelated to COVID-19 infection | 9 (4.0%) |
| Psychiatric evaluation | 7 (3.1%) |
| The goal was to help patients tolerate isolation in the facility. Required adaptations of usual practice, e.g., prescribing higher doses of buprenorphi-ne to suppress craving, were sometimes necessary. Addiction specialists could also offer stimulant or benzodiazepine prescriptions for stimulant or benzodiazepine use disorders, to suppress craving and deter leaving the unit. Cigarettes, usually banned from hospitals, were provided upon request, and smoking was permitted in an external courtyard. | |
| Withdrawal was common because patients were confined suddenly. All patients were assessed for withdrawal risk upon admission, and withdrawal treatment was available 24 hours per day. | |
| Some medical staff were uncomfortable managing SUDs. Changed telehealth regulations allowed addiction specialists to perform telehealth consults, including initiating buprenorphine/methadone. | |
| Initially, methadone was obtained via take-home doses for patients who were already enrolled in outside opioid treatment programs (OTPs).This was operationally burdensome. Buprenorphine was also contraindicated for some patients with opioid withdrawal or use disorder (if, for instance, they had been using illicitly obtained methadone or longer-acting fentanyl analogs, or they preferred methadone treatment). Therefore, medical staff consulted with the DEA and obtained the ability to start methadone onsite. | |
| Harm reduction specialists were onsite to provide education, naloxone, and rapid HIV tests.Safe injection supplies were offered to patients at the time of discharge. |